Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Jiangsu Hengrui Medicine Co Ltd (600276)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
45.67 +1.37    +3.09%
26/04 - Closed. Currency in CNY ( Disclaimer )
Type:  Equity
Market:  China
ISIN:  CNE0000014W7 
  • Volume: 30,817,319
  • Bid/Ask: 45.66 / 45.67
  • Day's Range: 44.17 - 45.79
Jiangsu Hengrui 45.67 +1.37 +3.09%

Jiangsu Hengrui Medicine Co Ltd Company Profile

 
Get an in-depth profile of Jiangsu Hengrui Medicine Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

20636

Equity Type

ORD

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.

Contact Information

Address No. 38, Huanghe Road Economic and Technological Development Zone
Lianyungang, 222000
China
Phone -
Fax -

Top Executives

Name Age Since Title
Piao Yang Sun 65 2003 Chairman of the Board of Directors
Guo Qiang Xiong 47 2013 Employee Representative Member of the Supervisory Committee
Jie Ping Sun 53 2003 Deputy GM & Director
Hong Bin Dai 47 2003 GM & Director
Lian Shan Zhang 61 2012 Deputy GM & Director
Kai Hong Yuan 58 2023 Chairman of the Supervisory Board
Jiahong Dong 62 2021 Independent Director
Congzhao Guo 50 2020 Director
Jin Yun Sun 51 2023 Independent Director
Qingsheng Zeng 48 2023 Independent Director
Ningjun Jiang 62 2023 Deputy GM & Director
Yu Xu 30 2022 Employee Representative Supervisor
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

600276 Comments

Write your thoughts about Jiangsu Hengrui Medicine Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email